本文關(guān)鍵詞：白介素-33在急性呼吸窘迫綜合征中的研究進(jìn)展　出處：《重慶醫(yī)科大學(xué)學(xué)報(bào)》2016年04期 　論文類型：期刊論文

  更多相關(guān)文章： 急性呼吸窘迫綜合癥 白介素- 細(xì)胞因子 警報(bào)素 信號(hào)通路

【摘要】：急性呼吸窘迫綜合征(acute respiratory distress syndrome,ARDS)是以頑固性低氧血癥和進(jìn)行性呼吸困難為主要臨床特點(diǎn)的綜合征,是危重癥患者死亡的主要原因之一。盡管,近年來醫(yī)療技術(shù)的迅猛發(fā)展和新的藥物的應(yīng)用使ARDS的預(yù)后有所改善,但其病死率仍高達(dá)40%~50%。因此,更充分的了解ARDS的發(fā)病機(jī)制,實(shí)現(xiàn)早期診斷,為臨床上ARDS的防治提供指導(dǎo)仍是呼吸和重癥醫(yī)學(xué)界研究的重點(diǎn)和熱點(diǎn)。白介素(interleukin,IL)-33是新近發(fā)現(xiàn)的IL-1家族成員,在炎癥、感染、自身免疫性疾病等多種疾病中發(fā)揮重要的警報(bào)素作用,促進(jìn)機(jī)體的炎癥反應(yīng),加重機(jī)體組織的損傷。故IL-33及其信號(hào)通路可能成為阻斷炎癥通路的級(jí)聯(lián)反應(yīng)的一個(gè)潛在的分子靶點(diǎn)。本文就IL-33在ARDS中的研究進(jìn)展做一綜述。
[Abstract]:Acute respiratory distress syndrome. ARDS is a syndrome characterized by intractable hypoxemia and progressive dyspnea, and is one of the leading causes of death in critically ill patients. In recent years, with the rapid development of medical technology and the application of new drugs, the prognosis of ARDS has been improved, but its mortality is still as high as 40%. Therefore, the pathogenesis of ARDS is fully understood. To achieve early diagnosis and provide guidance for the prevention and treatment of ARDS in clinic is still the focus and focus of the research of respiratory and critical medicine. IL)-33 is a newly discovered member of IL-1 family, which plays an important role in many diseases, such as inflammation, infection, autoimmune diseases and so on. Therefore, IL-33 and its signaling pathway may become a potential molecular target for blocking the cascade of inflammatory pathways. This paper reviews the progress of IL-33 in ARDS. State.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院急診醫(yī)學(xué)科和重癥醫(yī)學(xué)科;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(編號(hào):81570069)
【分類號(hào)】：R563.8
【正文快照】： 白介素(interleukin,IL)-33是IL-1家族的新成員,在正常人體組織中持續(xù)表達(dá)[1-2],具有核內(nèi)調(diào)控基因轉(zhuǎn)錄和核外調(diào)節(jié)炎癥反應(yīng)的雙重功能[3-4]。目前,IL-33作為炎癥細(xì)胞因子的作用及其作用機(jī)制越來越受到重視,本文就IL-33在ARDS這一以炎癥反應(yīng)為中心環(huán)節(jié)的臨床綜合征中的研究進(jìn)展，

本文編號(hào)：1356679